Medtronic received information via literature regarding predictors of survival in pediatric mitral valve replacement.All data were collected retrospectively from a single center between july 1, 1982 and december 31, 2019.The study population included 115 patients (predominantly female, median age 5.5 years, mean weight 15 kg).Multiple manufacturer¿s devices were implanted in the study population.Among all patients 36 were implanted with a medtronic melody (n=2), hancock ii (n=16), hancock conduit (n=7), or an ats mechanical valve (n=11).No unique device identifier numbers were provided.Among all patients, there were 11 early and 13 late deaths.Causes of death included myocardial infarction (mi), acute thrombosis, multi-organ failure, cerebral hemorrhage, congestive heart failure (chf) and sudden death.Based on the available information medtronic product was not directly associated with the death(s).Among all patients, adverse events included: stenosis, unspecified dysfunction, thrombosis, unspecified degeneration, endocarditis, complete heart block requiring permanent pacemaker implant, stroke, and congestive heart failure (chf).Based on the available information medtronic product may have been associated with the adverse event(s).No additional adverse patient effects or product performance issues were reported.
|